Quarterly Period Covered: This 10-Q filing covers McKessson Corp's third quarter of fiscal year 2026, ending December 31, 2025 (period from April 1, 2025 through December 31, 2025) Company Overview: McKessson Corp is a wholesale drug distributor (SIC code 5122) headquartered in Irving, Texas, with fiscal year ending March 31 Financial Statements Included: The filing contains consolidated…

Our analysis rates this filing BEARISH. McKESSON faces a HIGH concern environment driven by multiple material risk factors. The opioid litigation exposure (severity 8) represents a significant contingent liability with multi-year financial and reputational consequences. The elimination of two…

Concern level: HIGH (7.2/10). Key factors: Two high-severity risks identified with severity scores of 8 and 7 (opioid litigation and segment restructuring); Risk trend is INCREASING with overall risk score of 7.1/10; Material opioid litigation exposure creating contingent liabilities with multi-year cash flow impact and reputational damage.

Notable risk changes: Segment restructuring: Elimination of Oncology & Multispecialty and Prescription Technology Solutions segments (previously reported as operating segments) indicates strategic portfolio rationalization and potential margin pressure in divested areas; Asset dispositions accelerating: Canadian retail operations divested December 2024; Norway operations classified as held-for-sale as of December…

The model predicts MCK will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.